A. A. Kudakaeva

A. A. Kudakaeva

Auto-generated profile, based on publicly available information

A. A. Kudakaeva

Veltischev Research and Clinical Institute for pediatrics and pediatric surgery at the Pirogov Russian National Research Medical University

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2024 in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
Verified
Journal Article
Closed access
PDF file
AKA. A. Kudakaeva
A. A. Kudakaeva
IDIlya Dantsev
Ilya Dantsev
VVV. Yu. Voinova
V. Yu. Voinova
Parenti–Migno neurodevelopmental disorder is a rare syndromal form of intellectual disability in children, associated with the CHD5 gene, the prevalence of which is not established. Currently, 16 patients with this pathology have been described. CHD5 belongs to the conservative family of chromatin remodeler proteins, is part of the histone deacetylase NuRD complex, and is crucial for the early differentiation of neurons in the central nervous system and acts as a tumor suppressor. Recently, thanks to the application of whole-exome sequencing, the association of this gene with Parenti–Migno neurodevelopmental disorder was first described in patients with developmental delay, psycho-neurological disturbances, facial phenotype features, and skull pathology. We present a unique case of the disease associated with a new variant p.Arg1521Thr in the CHD5 gene, in a girl with intellectual and neurological impairments, craniofacial dysmorphism, as well as previously undescribed symptoms such as cleft lip and palate, hydrocephalus, and renal pathology. The cause of the disease was determined through whole-genome sequencing, which highlights the value of this method in the diagnosis of undifferentiated forms of intellectual disabilities.

30 December 2025 in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
Verified
Journal Article
Open access
PDF file
Anastasiia BuianovaAnastasiia Buianova
Anastasiia Buianova
ARA. V. Rozhkova
A. V. Rozhkova
OPOlga Pavlovna Parshina
Olga Pavlovna Parshina
AKA. A. Kudakaeva
A. A. Kudakaeva
EVEvgeny Vasilyev
Evgeny Vasilyev
ENE. A. Nikolaeva
E. A. Nikolaeva
X-linked dominant hypophosphatemic rickets is the most common inherited form of hypophosphatemic rickets, characterized by renal dysfunction, skeletal deformities, and other multi-organ complications. In Russia, since 2022, the first targeted therapy has been approved for clinical use — Burosumab, a monoclonal antibody directed against fibroblast growth factor 23. Initiation of treatment requires confirmation of the diagnosis through molecular genetic testing. This study presents two clinical case reports of patients with X-linked dominant hypophosphatemic rickets. The clinical diagnosis was established at the ages of 7 and 12 years based on a characteristic biochemical profile and radiographic findings. However, causative variants in the PHEX gene (c.2147+1197A>G and chrX:22030553_22033026del) were identified only after whole-genome sequencing, followed by detailed analysis of next-generation sequencing data.